Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03569371 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT03569371 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Incyte Corporation. The registered enrollment target is 10 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03569371, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
Conditions Studied
Interventions
- DRUG INCB054707
Study Locations (4)
California
- Investigative Site - Los Angeles
Florida
- Investigative Site - Tampa
New York
- Investigative Site - New York
Pennsylvania
- Investigative Site - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03569371
The ClinicalTrials.gov registry entry for NCT03569371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (98% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which INCB054707 is the first listed.
NCT03569371 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03569371 about?
NCT03569371 is a clinical study titled "A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa". The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
What is the current status of trial NCT03569371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-07-17. Estimated completion is 2019-04-22.
What conditions does trial NCT03569371 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT03569371?
The interventions under investigation include: INCB054707 (DRUG).
Who is sponsoring clinical trial NCT03569371?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03569371 being conducted?
This trial has 4 study locations across California, Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.